Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-06-14
2011-06-14
Desai, Anand (Department: 1656)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S252300, C424S094100
Reexamination Certificate
active
07960529
ABSTRACT:
A bone delivery conjugate having a structure selected from the group consisting of: A) X-Dn-Y-protein-Z; and B) Z-protein-Y-Dn-X, wherein X is absent or is an amino acid sequence of at least one amino acid; Y is absent or is an amino acid sequence of at least one amino acid; Z is absent or is an amino acid sequence of at least one amino acid; and Dnis a poly aspartate wherein n=10 to 16. Compositions comprising same and methods of use thereof.
REFERENCES:
patent: 6290952 (2001-09-01), Poelstra et al.
patent: 6420384 (2002-07-01), Weigele et al.
patent: 6436386 (2002-08-01), Roberts et al.
patent: 6455495 (2002-09-01), Orgel et al.
patent: 6905689 (2005-06-01), Schneidinger et al.
patent: 7763712 (2010-07-01), Crine et al.
patent: 2002/0183276 (2002-12-01), Millan et al.
patent: 2003/0158132 (2003-08-01), Kovesdi
patent: 2004/0023916 (2004-02-01), Millan et al.
patent: 2004/0234518 (2004-11-01), Crine et al.
patent: 2005/0276796 (2005-12-01), Tomatsu et al.
patent: 2007/0081984 (2007-04-01), Tomatsu et al.
patent: 2007/0081986 (2007-04-01), Tomatsu et al.
patent: 2009/0238814 (2009-09-01), Tomatsu et al.
patent: 2010/0008979 (2010-01-01), Tomatsu et al.
patent: 2010/0221234 (2010-09-01), Crine et al.
patent: 2010/0297119 (2010-11-01), Crine et al.
patent: 8070875 (1996-03-01), None
patent: 2000-327583 (2000-11-01), None
patent: 2002-541776 (2002-12-01), None
patent: WO 92/020371 (1992-11-01), None
patent: WO 98/35703 (1998-08-01), None
patent: WO 00/18954 (2000-04-01), None
patent: WO 00/50580 (2000-08-01), None
patent: WO 00/64486 (2000-11-01), None
patent: WO 02/15918 (2002-02-01), None
patent: WO 02/068579 (2002-09-01), None
patent: WO 2005/103263 (2005-11-01), None
patent: WO 2006/039480 (2006-04-01), None
patent: WO 2008/138131 (2008-11-01), None
Remarks filed in U.S. Appl. No. 11/111,664 dated Sep. 10, 2008, pp. 6-10.
Addison et al., “Pyrophosphate Inhibits Mineralization of Osteoblast Cultures by Binding to Mineral, Up-regulating Osteopontin, and Inhibiting Alkaline Phosphate Activity,”J. Biol. Chem. 282:15872-15883, 2007.
Anderson et al., “Impaired Calcification Around Matrix Vesicles of Growth Plate and Bone in Alkaline Phosphatase-deficient Mice,”Am. J. Pathol. 164:841-847, 2004.
Bernardi et al., “Chromatography of Proteins on Hydoxyapatite,”Methods in Enzymology27:471-479, 1973.
Bobé et al., “Fas-Mediated Liver Damage in MRL Hemopoietic Chimeras Undergoing Ipr-Mediated Graft-Versus-Host Disease,”J. Immunol. 159:4197-4204, 1997.
Campbell et al., “Insulin-Like Growth Factor (IGF)-Binding Protein-5-(201-218) Region Regulates Hydroxyapatite and IGF-I Binding,”Am. J. Physiol. 273:E1005-1013, 1997.
Ciancaglini et al., “Contribution of Matrix Vesicles and Alkaline Phosphatase to Ectopic Bone Formation,”Braz. J. Med. Biol. Res. 39:603-610, 2006.
Data Sheet for pFUSE-SEAP-hFC, Invivogen, San Diego, CA, 1989.
Di Mauro et al., “Kinetic Characterization of Hypophosphatasia Mutations with Physiological Substrates,”J. Bone Miner. Res. 17:1383-1391, 2002.
Dumont et al., “Monomeric Fc Fusions: Impact on Pharmacokinetic and Biological Activity of Protein Therapeutics,”BioDrugs20:151-160, 2006.
Fujisaki et al., “Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. I.v. Effects of Osteotropic Estradiol on Bone Mineral Density and Uterine Weight in Ovariectomized Rats,”J. Drug Target. 5:129-138, 1997.
Fujisawa et al., “Acidic Amino Acid-Rich Sequences as Binding Sites of Osteonectin to Hydroxyapatite Crystals,”Biochim. Biophys. Acta1292:53-60, 1996.
Gilbert et al., “Chimeric Peptides of Statherin and Osteopontin that Bind Hydroxyapatite and Mediate Cell Adhesion,”J. Biol. Chem. 275:16213-16218, 2000.
Halling Linder et al., “Glycosylation Differences Contribute to Distinct Catalytic Properties Among Bone Alkaline Phosphotase Isoforms,”Bone45:987-993, 2009.
Henthorn and Whyte, “Missense Mutations of the Tissue Non-Specific Alkaline Phosphatase Gene in Hypophosphatasia,”Clin. Chem. 38:2501-2505, 1992.
Hosain et al., “Targeted Delivery of Antineoplastic Agent to Bone: Biodistribution Studies of Technetium-99m-Labeled Gem-Bisphosphonate Conjugate of Methotrexate,”J. Nucl. Med. 37:105-107, 1996.
Hunter et al., “Modulation of Crystal Formation by Bone Phosphoproteins: Structural Specificity of the Osteopontin-Mediated Inhibition of Hydroxyapatite Formation,”Biochem. J. 300:723-728, 1994.
Ikezawa, “Glycosylphosphatidylinositol (GPI)-anchored Proteins,”Biol. Pharm. Bull. 25:409-417, 2002.
Kasugai et al., “Selective Drug Delivery System to Bone: Small Peptide (Asp)6 Conjugation,”J. Bone Miner. Res. 15:936-943, 2000.
Kaufmann et al., “Influence of Low Temperature on Productivity, Proteome and Protein Phosphorylation of CHO Cells,”Biotechnol. Bioeng. 63:573-582, 1999.
Millán, “Mammalian Alkaline Phosphatases,” inBiology to Applications in Medicine and Biotechnology, pp. 107-185, 2006 (Wiley-VCH Verlag).
Millán et al., “Enzyme Replacement Therapy for Murine Hypophosphatasia.”J. Bone Miner. Res. 23: 777-787, 2008 (Epublished ahead of print on Dec. 17, 2007).
Murshed et al., “Unique Coexpression in Osteoblasts of Broadly Expressed Genes Accounts for the Spatial Restriction of ECM Mineralization to Bone,”Genes Dev. 19:1093-1104, 2005.
Nishioka et al., “Enhancement of Drug Delivery to Bone: Characterization of Human Tissue-Nonspecific Alkaline Phosphatase Tagged with an Acidic Oligopeptide,”Mol. Genet. Metab. 88:244-255, 2006.
Oda et al., “A General Method for Rapid Purification of Soluble Versions of Glycosylphosphatidylinositol-Anchored Proteins Expressed in Insect Cells: An Application for Human Tissue-Nonspecific Alkaline Phosphatase,”J. Biochem. 126:694-699, 1999.
Patti et al., “Critical Residues in the Ligand-Binding Site of theStaphylococcus aureusCollagen-Binding Adhesin (MSCRAMM),”J. Biol. Chem. 270:12005-12011, 1995.
Rezende et al., “Inorganic Pyrophosphate-phosphohydrolitic Activity Associated with Rat Osseous Plate Alkaline Phosphatase,”Cell. Mol. Biol. (Noisy-le-grand) 44:293-302, 1998.
Rowe et al., “MEPE, A New Gene Expressed in Bone Marrow and Tumors Causing Osteomalacia,”Genomics67:54-68, 2000.
Salih et al., “Identification of the Phosphorylated Sites of Metabolically 32P-Labeled Osteopontin from Cultured Chicken Osteoblasts,”J. Biol. Chem. 272:13966-13973, 1997.
Sekido et al., “Novel Drug Delivery System to Bone Using Acidic Oligopeptide: Pharmacokinetic Characteristics and Pharmacological Potential,”J. Drug Target. 9:111-121, 2001.
Sharom and Lehto, “Glycosylphosphatidylinositol-Anchored Proteins: Structure, Function, and Cleavage by Phosphatidylinositol-Specific Phospholipase C,”Biochem. Cell. Biol. 8:535-549, 2002.
Shull et al., “Enzyme Replacement in a Canine Model of Hurler Syndrome,”Proc. Natl. Acad. Sci. USA91:12937-12941, 1994.
Spears et al., “Deoxyuridylate Effects on Thymidylate Synthase-5-Fluorodeoxyuridylate-Folate Ternary Complex Formation,”Biochem. Pharmacol. 38:2985-2993, 1989.
Sturtz et al., “A Study of the Delivery-Targeting Concept Applied to Antineoplasic Drugs Active on Human Osteosarcoma. I. Synthesis and Biological Activity in Nude Mice Carrying Human Osteosarcoma Xenografts of Gem-Bisphosphonic Methotrexate Analogues,”Eur. J. Med. Chemistry27:825-833, 1992.
Symersky et al., “Structure of the Collagen-Binding Domain From aStaphylococcus aureusAdhesin,”Nat. Struct. Biol. 4:833-838, 1997.
Uludag et al., “Bone Affinity of a Bisphosphonate-Conjugated Protein In Vivo,”Biotechnol. Prog. 16:1115-1118, 2000.
Weinberg, “An Overview of Infliximab, Etanercept, Efalizumab, and Alefacept as Biologic Therapy for Psoriasis,”Clin. Ther. 25:2487-2505, 2003.
Weiss et
Boileau Guy
Crine Philippe
Lemire Isabelle
Loisel Thomas P.
Bieker-Brady Kristina
Clark & Elbing LLP
Desai Anand
Enobia Pharma Inc.
Robinson Michael A.
LandOfFree
Bone delivery conjugates and method of using same to target... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bone delivery conjugates and method of using same to target..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bone delivery conjugates and method of using same to target... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2651450